{
    "organizations": [],
    "uuid": "4905d61e7f5ff0e2bb0280c0827c44bde718c375",
    "author": "",
    "url": "https://www.reuters.com/article/brief-zynerba-pharmaceuticals-reports-q4/brief-zynerba-pharmaceuticals-reports-q4-loss-per-share-0-60-idUSASC09RPX",
    "ord_in_thread": 0,
    "title": "BRIEF-Zynerba Pharmaceuticals Reports Q4 Loss Per Share $0.60",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "March 12, 2018 / 11:00 AM / in 7 minutes BRIEF-Zynerba Pharmaceuticals Reports Q4 Loss Per Share $0.60 Reuters Staff March 12 (Reuters) - Zynerba Pharmaceuticals Inc: * ZYNERBA PHARMACEUTICALS REPORTS FOURTH QUARTER AND YEAR END 2017 FINANCIAL RESULTS AND OPERATIONAL HIGHLIGHTS * Q4 LOSS PER SHARE $0.60 * Q4 EARNINGS PER SHARE VIEW $-0.60 — THOMSON REUTERS I/B/E/S * ‍EXPECTS TO INITIATE STUDY MID-YEAR 2018 TO SUPPORT AN NDA FOR ZYN002 IN FXS​ * ZYNERBA PHARMACEUTICALS - BELIEVES ‍CASH,CASH EQUIVALENT POSITION AS OF DEC 31, 2017 IS SUFFICIENT TO FUND OPERATIONS, CAPITAL REQUIREMENTS WELL INTO 2019​ * ZYNERBA - BELIEVES CASH, CASH EQUIVALENT POSITION OF $62.5 MILLION AS OF DEC 31, 2017 SUFFICIENT TO FUND OPERATIONS, CAPITAL REQUIREMENTS WELL INTO 2019 Source text for Eikon: Further company coverage:",
    "published": "2018-03-12T12:57:00.000+02:00",
    "crawled": "2018-03-12T13:13:42.005+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "march",
        "minute",
        "pharmaceutical",
        "report",
        "q4",
        "loss",
        "per",
        "share",
        "reuters",
        "staff",
        "march",
        "reuters",
        "zynerba",
        "pharmaceutical",
        "inc",
        "zynerba",
        "pharmaceutical",
        "report",
        "fourth",
        "quarter",
        "year",
        "end",
        "financial",
        "result",
        "operational",
        "highlight",
        "q4",
        "loss",
        "per",
        "share",
        "q4",
        "earnings",
        "per",
        "share",
        "view",
        "thomson",
        "reuters",
        "initiate",
        "study",
        "support",
        "nda",
        "zyn002",
        "zynerba",
        "pharmaceutical",
        "belief",
        "cash",
        "equivalent",
        "position",
        "dec",
        "sufficient",
        "fund",
        "operation",
        "capital",
        "requirement",
        "well",
        "zynerba",
        "belief",
        "cash",
        "cash",
        "equivalent",
        "position",
        "million",
        "dec",
        "sufficient",
        "fund",
        "operation",
        "capital",
        "requirement",
        "well",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}